Heart Failure Reviews

, 9:203 | Cite as

Practical Application of Human B-Type Natriuretic Peptide as a Therapeutic Intervention in the Perioperative Setting

Article

Abstract

The use of human B-type natriuretic peptide (BNP, nesiritide) as a therapeutic intervention is now well established for patients with acute decompensated heart failure. Nesiritide mimics the actions of endogenous BNP by binding to and stimulating receptors in the heart, kidney, and vasculature. Postsurgical patients are typically managed with various combinations of vasodilators, diuretics, and inotropes. Many of these therapeutic interventions lack significant proof of efficacy and are potentially deleterious to these patients, despite the acute hemodynamic improvement that results from their use. Use of nesiritide may supplant some of these therapies as an equally efficacious and possibly safer alternative in patients with decompensated heart failure. Nesiritide is a unique, balanced vasodilator that markedly decreases the signs and symptoms of heart failure in perioperative patients, and also may decrease the need for inotropic agents. This review summarizes nesiritide’s mechanism of action and addresses special concerns and practical considerations for cardiothoracic surgeons and anesthesiologists. Overall, nesiritide appears to be an effective and safe therapeutic option in perioperative patients with decompensated heart failure.

Keywords

cardiothoracic surgery heart failure inotropic therapy nesiritide vasodilator therapy 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    American Heart Association. Heart Disease and Stroke Statistics—2003 Update. American Heart Association. Available at: http://www.americanheart.org/downloadable/heart/1040391091015HDS_Stats_03.pdf. Accessed August 28, 2003.
  2. 2.
    Luciani GB, Menon T, Vecchi B, Auriemma S, Mazzucco A. Modified ultrafiltration reduces morbidity after adult cardiac operations: A prospective, randomized clinical trial. Circulation 2001;104:I253–I259.PubMedGoogle Scholar
  3. 3.
    Moazami N, Damiano RJ, Bailey MS, et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003;75:1974–1976.PubMedGoogle Scholar
  4. 4.
    Entwistle JWC, III, McLoughlin DE, Baghelai K. Postoperative nesiritide use following high-risk mitral valve. The Heart Surgery Forum 2004;7:E189–E190.PubMedGoogle Scholar
  5. 5.
    Feldman DS, Ikonomidis JS, Uber WE, et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004;10:292–296.PubMedGoogle Scholar
  6. 6.
    Delgado RM, Radovancevic B, Vrtovec B, et al. Perioperative use of neseritide in heart failure patients undergoing implantation of left ventricular assist device [abstract 417]. J Card Fail 2003;9(Suppl):S111.Google Scholar
  7. 7.
    Delgado RM, III, Radovancevic B, Kar B, et al. Effect of nesiritide on renal function after implantation of the AbioCor total artificial heart [abstract 1059–30]. J Am Coll Cardiol 2004;43 (Suppl A):17A.Google Scholar
  8. 8.
    Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am Heart J 2002;144:1102–1108.PubMedGoogle Scholar
  9. 9.
    Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798–803.PubMedGoogle Scholar
  10. 10.
    Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697–2701.PubMedGoogle Scholar
  11. 11.
    Iyengar S, Feldman DS, Trupp R, Abraham WT. Nesiritide for the treatment of congestive heart failure. Expert Opin Pharmacother 2004;5:901–907.PubMedGoogle Scholar
  12. 12.
    Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246–253.PubMedGoogle Scholar
  13. 13.
    Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184–3189.PubMedGoogle Scholar
  14. 14.
    Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996;9:432–436.PubMedGoogle Scholar
  15. 15.
    Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 1999;96:5–15.CrossRefGoogle Scholar
  16. 16.
    Grantham JA, Borgeson DD, Burnett JC, Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 1997;272:R1077–R1083.PubMedGoogle Scholar
  17. 17.
    Kasahara M, Mukoyama M, Sugawara A, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000;11:1691–1701.PubMedGoogle Scholar
  18. 18.
    Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081–1088.PubMedGoogle Scholar
  19. 19.
    Hutfless R, Kazanegra R, Madani M, et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004;43:1873–1879.PubMedGoogle Scholar
  20. 20.
    Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004;110:124–127.PubMedGoogle Scholar
  21. 21.
    Watanabe M, Egi K, Hasegawa S, et al. Significance of serum atrial and brain natriuretic peptide release after coronary artery bypass grafting. Surg Today 2003;33:671–673.PubMedGoogle Scholar
  22. 22.
    Song MH, Kobayashi Y, Michi H. Clinical implication of atrial and brain natriuretic Peptide in coronary artery bypass grafting. Asian Cardiovasc Thorac Ann 2004;12:41–46.PubMedGoogle Scholar
  23. 23.
    Schenk S, McCarthy PM, Starling RC, et al. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2004;128:38–43.PubMedGoogle Scholar
  24. 24.
    Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531–1540.Google Scholar
  25. 25.
    Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am J Cardiol 2004;94:595–601.PubMedGoogle Scholar
  26. 26.
    Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37–44.PubMedGoogle Scholar
  27. 27.
    Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97:4239–4244.PubMedGoogle Scholar
  28. 28.
    Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999;276(3 pt 2):H1049–H1057.PubMedGoogle Scholar
  29. 29.
    Krämer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999;106:90–96.PubMedGoogle Scholar
  30. 30.
    Clemens LE, Almirez RG, Baudouin KA, Mischak RP, Grossbard EB, Protter AA. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther 1998;287:67–71.PubMedGoogle Scholar
  31. 31.
    Abraham WT, Lewis D, Trupp RJ. Changing algorithms for the management of acutely decompensated congestive heart failure. Rev Cardiovasc Med 2001;2:235–236.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Divisions of Cardiology and Cardiothoracic SurgeryThe Ohio State University Medical CenterColumbusUSA
  2. 2.200 Heart Lung Research InstituteColumbusUSA

Personalised recommendations